Orthofix officer’s tax-related sale of 4,269 shares

Orthofix Medical Inc. executive Lucas Vitale, Chief People & Business Operations Officer, reported an open-market sale of 4,269 shares of common stock at $11.92 per share.

Rhea-AI Filing Summary

Orthofix Medical Inc. executive Lucas Vitale, Chief People & Business Operations Officer, reported an open-market sale of 4,269 shares of common stock at $11.92 per share. According to the disclosure, the sale was executed solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-approved sell-to-cover arrangement.

The transaction was carried out without any exercise of discretion by Vitale. Following this tax-related sale, he holds 160,449 shares of Orthofix common stock, which includes 127,256 previously reported restricted stock units.

Insider Trade Summary

Net Seller: 4,269 shares

Net Sell 1 txn

Insider Vitale Lucas

Role CP&BOO

Sold 4,269 shs ($51K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,269	$11.92	$51K

Holdings After Transaction: Common Stock — 160,449 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
2. F2. Includes 127,256 previously reported restricted stock units.

FAQ

What did Orthofix (OFIX) executive Lucas Vitale report in this Form 4?

Lucas Vitale reported selling 4,269 shares of Orthofix common stock at $11.92 per share. The transaction was tied to tax withholding obligations from restricted stock unit settlement, under a pre-approved sell-to-cover arrangement with no discretionary trading by Vitale.

Why did Lucas Vitale sell Orthofix (OFIX) shares in this transaction?

The shares were sold to cover tax withholding obligations from the settlement of restricted stock units. The filing states this was done under a pre-existing, mandated sell-to-cover requirement approved by the Compensation and Talent Development Committee, without any trading discretion by Vitale.

How many Orthofix (OFIX) shares does Lucas Vitale hold after the reported sale?

After the transaction, Vitale holds 160,449 shares of Orthofix common stock. This total includes 127,256 previously reported restricted stock units, indicating he retains a substantial equity position in the company despite the tax-related sale.

Was the Orthofix (OFIX) insider sale by Lucas Vitale part of a trading plan?

Yes. The sale occurred pursuant to a pre-existing sell-to-cover requirement approved and mandated by the Compensation and Talent Development Committee. This arrangement automatically sold shares to satisfy tax obligations, and the filing notes Vitale exercised no discretion over the sale.

Does the Orthofix (OFIX) Form 4 indicate any option exercises by Lucas Vitale?

No option or other derivative exercises are shown in this Form 4. The reported transaction involves only common stock sold to cover taxes on restricted stock unit settlement, and the derivative position summary in the data provided is empty.

What role does Lucas Vitale hold at Orthofix (OFIX) in this Form 4?

Lucas Vitale is identified as an officer of Orthofix with the title Chief People & Business Operations Officer. The reported transaction reflects his personal equity activity related to compensation, specifically tax withholding on restricted stock unit settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitale Lucas

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TEXAS 75056

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CP&BOO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		4,269	D	$11.92	160,449(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

2. Includes 127,256 previously reported restricted stock units.

	/s/ J. Andres Cedron, attorney-in-fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)